SeekingAlpha · Nov 6, 2026
CytomX Therapeutics, Inc. (CTMX) Q3 2026 Earnings Call Transcript
CytomX Therapeutics, Inc. (CTMX) Q3 2026 Earnings Call November 5, 2026 5:00 PM ESTCompany ParticipantsChris Ogden - SVP, CFO & SecretarySean McCarthy -...

NASDAQ · CTMX
Healthcare · Biotechnology
$1.99
Down-$0.06 (-2.70%)
Updated Nov 17, 2026, 5:34 AM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CTMX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 16, 2026
CTMX closed at $1.99 after 21 trading sessions, down 15.17% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 16, 2026 | $2.02 | $2.08 | $1.94 | $1.985 | 2.6M |
| Nov 13, 2026 | $2.02 | $2.1252 | $1.96 | $2.04 | 2.72M |
| Nov 12, 2026 | $2.15 | $2.18 | $2.03 | $2.04 | 3.16M |
| Nov 11, 2026 | $1.99 | $2.17 | $1.96 | $2.13 | 4.99M |
| Nov 10, 2026 | $1.99 | $2.02 | $1.90 | $1.98 | 16.65M |
| Nov 9, 2026 | $2.24 | $2.28 | $1.95 | $1.98 | 12.91M |
| Nov 6, 2026 | $2.24 | $2.27 | $2.1201 | $2.19 | 2.73M |
| Nov 5, 2026 | $2.35 | $2.35 | $2.11 | $2.14 | 3.86M |
| Nov 4, 2026 | $2.26 | $2.36 | $2.175 | $2.35 | 6.59M |
| Nov 3, 2026 | $2.24 | $2.32 | $2.155 | $2.18 | 3.41M |
| Nov 2, 2026 | $2.36 | $2.39 | $2.14 | $2.23 | 9.47M |
| Oct 30, 2026 | $2.28 | $2.36 | $2.21 | $2.34 | 4.94M |
| Oct 29, 2026 | $2.38 | $2.42 | $2.25 | $2.29 | 4.63M |
| Oct 28, 2026 | $2.28 | $2.385 | $2.25 | $2.36 | 4.08M |
| Oct 27, 2026 | $2.21 | $2.36 | $2.16 | $2.31 | 3.73M |
| Oct 26, 2026 | $2.31 | $2.33 | $2.18 | $2.225 | 5.22M |
| Oct 23, 2026 | $2.41 | $2.42 | $2.305 | $2.32 | 4.37M |
| Oct 22, 2026 | $2.38 | $2.47 | $2.37 | $2.44 | 2.44M |
| Oct 21, 2026 | $2.525 | $2.61 | $2.39 | $2.40 | 3.11M |
| Oct 20, 2026 | $2.36 | $2.55 | $2.34 | $2.51 | 4.1M |
| Oct 19, 2026 | $2.31 | $2.35 | $2.24 | $2.34 | 2.05M |
The latest Smart Investors Daily articles mentioning CTMX.
Company
Market Activity
Research & News
CTMX research
Company profile and research snapshot.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 12, 2026 | JP Morgan | Overweight | — |
| Nov 6, 2026 | Wedbush | Outperform | — |
| Aug 13, 2026 | JP Morgan | Overweight | — |
| Aug 10, 2026 | Guggenheim | Buy | — |
| May 11, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Nov 6, 2026
CytomX Therapeutics, Inc. (CTMX) Q3 2026 Earnings Call November 5, 2026 5:00 PM ESTCompany ParticipantsChris Ogden - SVP, CFO & SecretarySean McCarthy -...
Benzinga · Nov 6, 2026
Wedbush analyst Robert Driscoll maintains CytomX Therapeutics (NASDAQ:CTMX) with a Outperform and raises the price target from $11 to $12.
Yahoo · Nov 6, 2026
Lower diarrhea rates emerge, but toxicity control remains the key test.
Yahoo · Nov 6, 2026
CytomX Therapeutics (NASDAQ:CTMX) plans to provide a January update on its lead cancer drug candidate, Varseta-M, as it prepares for a potential registrational study in metastatic colorectal cancer in the first half of 2027. The update is expected to include the first look at overall survival data
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning CTMX.